Adiponil Capsule: Each capsule contains Orlistat INN 120 mg
Adiponil is a potent, specific and reversible long acting inhibitor of gastrointestinal lipases for obesity management that acts by inhibiting the absorption of dietary fat. It exerts its therapeutic activity in the human stomach and small intestine by forming a covalent bond with the active serine residue of the active site of gastric and pancreatic lipases. The inactivated enzymes are thus unable to hydrolyze the dietary fat in the form of triglycerides, into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting calorie deficit has a positive effect on weight control. Systemic absorption of the drug is therefore not needed for activity. At the recommended therapeutic dose of 120 mg three times a day, Orlistat inhibits dietary fat absorption by approximately 30 %.
Adiponil is indicated for long term treatment of significantly obese patients, including patients with risk factors associated with obesity, in conjunction with a mildly hypocaloric diet. Adiponil is also indicated in long term weight control such as weight loss, weight maintenance and prevention of weight regain
Dosage & Administration
The recommended dose of Adiponil is one 120 mg capsule three times a day with each main meal (during or upto 1 hour after the meal).
Generally Adiponil is well tolerated. However few side effects including oily spotting, flattus with discharge, faecal urgeney, oily evaculation, increased defaecation may be seen after administration of orlistat
Patients should be advised to adhere to dietary guidelines. gastrointestinal events may increase when orlistat is taken with a diet high in fat (>30% of calories from fat). The daily intake of fat should be distributed over three main meals. If a meal is missed, the dose of orlistat may be omitted.
Use in Pregnancy & Lactation
There are no adequate and well controlled studies of orlistat in pregnant women. Orlistat is not recommended for use during pregnancy.
It is not known if orlistat is secreted in human breast milk. Orlistat should not be taken by nursing women.
Single doses of 800 mg and multiple doses of up to 400 mg three times a day for 15 days have been studied in normal weight and obese subjects without significant adverse findings. If a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 hours. Based on human and animal studies, any systemic effects attributable to the lipase inhibiting properties of orlistat should be rapidly reversible
Adiponil capsule: Each box contains 1 blister strip of 10 capsules